02197 CLOVER BIO-B
- 0.255
- +0.005+2.00%
CLOVER BIO-B News
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Adidas Consortium-B (02197) SCB-1019: The potential best in its class, reshaping the global RSV market landscape
With its unique Trimer-Tag technology platform, Clover Biopharmaceuticals' RSV candidate vaccine SCB-1019 is expected to be a potential best-in-class, reshaping the market landscape of RSV vaccines~
Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.
①What is the impact of medical insurance negotiations on pharmaceutical stocks? ②What are the reasons for the rise of Tri Clover Biopharmaceutical and Yimington Corporation?
Hong Kong Stock Market News | Clover Biopharmaceuticals-B (02197) surged more than 14%, positive results from Phase I study of bivalent RSV vaccine.
Adidas AG (02197) rose over 14%, as of the time of publication, up 14.75% to 0.35 Hong Kong dollars, with a turnover of 0.8356 million Hong Kong dollars.
Express News | Clover Announces Positive Clinical Data for Rsv Vaccine Candidate Scb-1019 Compared Head-to-Head Versus GSK's Arexvy
Adidas Biologics-B (02197.HK) announced positive clinical data from the head-to-head comparison of its bivalent RSV candidate vaccine SCB-1019 with the GSK RSV vaccine AREXVY.
Grain Live 29th October | Clover Biopharmaceuticals-B (02197.HK) announced that in Phase I clinical trial, the divalent RSV PreF trimer subunit candidate vaccine SCB-1019 (developed based on Clover Biopharmaceuticals' unique Trimer-Tag protein trimerization vaccine technology platform) evaluated without the use of adjuvants, obtained more positive immunogenicity and safety data in elderly subjects compared to GSK's RSV vaccine AREXVY using AS01E adjuvant in a head-to-head comparison.
CLOVER BIO-B: 2024 Interim Report
Adidas Group Bio-B (02197) fell by 51.00%, now at 0.206 yuan, hitting a 52-week low.
As of 10:13, TripleLeaf Biology-B (02197) fell by 51.00% from the previous closing price to 0.206 yuan, hitting a 52-week low; with a volume of 0.017 million shares and a turnover of 0.0035 million Hong Kong dollars.
Clover Biopharmaceuticals Swings to Loss in H1
Trifolium Biotech - B (02197) releases its interim performance. Shareholders' net loss amounted to 95.123 million yuan, turning from a year-on-year profit to a loss.
The performance of the biotechnology company Trinity (02197) for the six months ended June 30, 2024, was announced by the group...
Express News | Clover Biopharmaceuticals H1 Net Income RMB -95.1 Million
CLOVER BIO-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Hong Kong stock concept tracking | Sanofi suspends supply and sales of flu vaccines domestically, attention on domestic vaccines (concept stocks attached)
Due to efficacy issues, Sanofi has decided to temporarily suspend the supply and sales of influenza vaccines in China.
Adidas AG-B (02197.HK) will hold a Board of Directors meeting on August 27 to approve its interim results.
Three Blades Biotech-B (02197.HK) announced on August 16th that the board of directors will hold a meeting on August 27th, 2024 to consider and approve the mid-year performance of the company and its subsidiaries as of June 30th, 2024, and to consider the distribution of mid-year dividends (if any).
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Express News | Clover Biopharmaceuticals Ltd: Full Phase Ⅰ Data Readout Is Planned by Year-End 2024
Express News | Clover Biopharmaceuticals: Bivalent Scb-1019 Significantly Boosted Rsv-a and Rsv-B Neutralizing Antibody Titers in Older Adults
Express News | Clover Biopharmaceuticals Ltd: Study Showed Favorable Safety & Reactogenicity Profile Comparable to Saline Placebo
Express News | Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent Rsv Vaccine Candidate Scb-1019 in Older Adults
No Data
